Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY517717

Known as: LY 517717, LY-517717 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blood coagulation at various… Expand
Is this relevant?
Review
2013
Review
2013
After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most… Expand
  • figure 1
  • figure 2
  • table 4
Is this relevant?
Review
2012
Review
2012
Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… Expand
Is this relevant?
Review
2008
Review
2008
In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has… Expand
Is this relevant?
2007
2007
BACKGROUND LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development. OBJECTIVES… Expand
Is this relevant?
Review
2007
Review
2007
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… Expand
  • table 3
  • table 1
  • table 2
Is this relevant?
Review
2007
Review
2007
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2007
2007
12B75, 274150; Abacavir sulfate/lamivudine, Abatacept, Ad2/HIF-1alpha, Adalimumab, Adefovir, Adefovir dipivoxil, AGN-201904-Z… Expand
Is this relevant?
2007
2007
  • 2007
  • Corpus ID: 195118277
 
Is this relevant?
2007
2007
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the… Expand
Is this relevant?